You are here: Home » Companies » News
Business Standard

Lupin gets USFDA's final nod to market generic Tamiflu

Lupin shall commence promoting the product shortly, it added

Press Trust of India  |  New Delhi 

An employee of Lupin Limited works at a reception at their headquarters in Mumbai

Drug firm today said it has received final nod from the US health regulator to market its Phosphate for oral suspension used for treatment of in

The company has received final approval to market its generic Phosphate for oral suspension from the Food and Drug Administration (USFDA), said in a filing to BSE.

The company's product is a generic version of Hoffman-La Roche Inc's Tamiflu for oral suspension, 6 mg/mL, it added.

shall commence promoting the product shortly, it added.

As per IQVIA MAT October 2017 data, Phosphate for oral suspension, 6 mg (base)/mL had annual sales of approximately USD 358 million in the US, Lupin said.

The product is "indicated for the treatment of acute, uncomplicated A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and prophylaxis of A and B in patients 1 year and older, " it added.

Shares of Lupin were today trading at Rs 813.50 per scrip in the afternoon trade on BSE, down 0.28 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Wed, February 21 2018. 17:24 IST